• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypopigmentation of the Skin and Hair Associated with Dasatinib Therapy.

作者信息

Sharma Vishnu, Bagrodia Vansh

机构信息

Medicine Department at SMS Medical College, Jaipur, India

SMS Medical College, Jaipur, India

出版信息

Turk J Haematol. 2024 May 30;41(2):116-117. doi: 10.4274/tjh.galenos.2023.2023.0280. Epub 2023 Sep 12.

DOI:10.4274/tjh.galenos.2023.2023.0280
PMID:37698254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11589257/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d76/11589257/e134e7d5a61c/TurkJHematol-41-116-figure-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d76/11589257/387c6a5616a9/TurkJHematol-41-116-figure-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d76/11589257/e134e7d5a61c/TurkJHematol-41-116-figure-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d76/11589257/387c6a5616a9/TurkJHematol-41-116-figure-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d76/11589257/e134e7d5a61c/TurkJHematol-41-116-figure-2.jpg

相似文献

1
Hypopigmentation of the Skin and Hair Associated with Dasatinib Therapy.与达沙替尼治疗相关的皮肤和毛发色素减退
Turk J Haematol. 2024 May 30;41(2):116-117. doi: 10.4274/tjh.galenos.2023.2023.0280. Epub 2023 Sep 12.
2
Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib.使用质子泵抑制剂与接受达沙替尼治疗的慢性髓性白血病患者的不良结局无关。
Clin Lymphoma Myeloma Leuk. 2024 Jul;24(7):484-487. doi: 10.1016/j.clml.2024.02.014. Epub 2024 Feb 29.
3
Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?对于新诊断的慢性期慢性髓性白血病患者，50毫克/天是达沙替尼的新标准剂量吗？
Expert Rev Hematol. 2024 Jul;17(7):275-277. doi: 10.1080/17474086.2024.2370556. Epub 2024 Jun 25.
4
Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
J Drugs Dermatol. 2009 Apr;8(4):395-8.
5
Is dasatinib-related pulmonary hypertension a clinical concern?达沙替尼相关的肺动脉高压是一个临床关注点吗？
Future Oncol. 2015 Sep;11(18):2491-4. doi: 10.2217/fon.15.170. Epub 2015 Aug 17.
6
Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia.达沙替尼诱导的可逆性脱髓鞘周围神经病，并成功转换为慢性髓性白血病的尼洛替尼。
Intern Med. 2020 Oct 1;59(19):2419-2421. doi: 10.2169/internalmedicine.4824-20. Epub 2020 Jun 30.
7
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.接受新一代BCR-ABL酪氨酸激酶抑制剂治疗的慢性髓性白血病患者发生动脉和静脉闭塞事件的风险：一项系统评价和荟萃分析。
Expert Opin Drug Saf. 2017 Jan;16(1):5-12. doi: 10.1080/14740338.2017.1261824. Epub 2016 Nov 28.
8
[Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].[慢性髓性白血病患者中与酪氨酸激酶抑制剂相关的肝脏不良事件]
Zhonghua Nei Ke Za Zhi. 2018 Sep 1;57(9):649-655. doi: 10.3760/cma.j.issn.0578-1426.2018.09.006.
9
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.二线达沙替尼治疗改善了不耐受伊马替尼的慢性髓性白血病患者的依从性和深度分子反应。
Anticancer Res. 2020 Sep;40(9):5313-5317. doi: 10.21873/anticanres.14538.
10
Vascular events may predict the prognosis of patients with chronic myeloid leukemia.血管事件可能预测慢性髓性白血病患者的预后。
Int J Hematol. 2020 Aug;112(2):263. doi: 10.1007/s12185-020-02889-8. Epub 2020 Jun 12.